Professional Marketing briefs: December 2012
The scandal over Diovan draws regulatory attention.
Eli Lilly is expanding its Indiana insulin manufacturing operations, marking the first expansion of the company's Indianapolis sites in more than twenty years. The company noted in a statement that the new capacity is to meet US demand.
Novartis continues to focus on making Singapore its biotech and manufacturing hub. The company announced October 31 that it was investing more than $500 million in building a manufacturing facility that will focus on drugs based on cell culture technology. The company said in a statement it expects work to wrap by 2016.
Fallout from Johnson & Johnson's disappointing Alzheimer's drug trials continue to pile up. The company is now laying off 130 employees from the San Francisco office of its Janssen Alzheimer's Immunotherapy unit, reported Pharmalot. Bapineuzumab was a joint effort that included Johnson & Johnson, Pfizer and Elan.Pfizer is laying off 300 employees in Canada, the Canadian Broadcast Wire reported October 28. The layoffs will shrink Pfizer's northern footprint from 2,700 employees to 2,400. Most of the cuts will be at the Montreal-area headquarters.